EMEA Anorexiants Market – Industry Trends and Forecast to 2030

EMEA Anorexiants Market, By Drug Class (Catecholamines Anorexiants, Serotonin Anorexiants), Drug Type (Generics, Branded), Applications (Weight Loss, Obesity, Attention Deficit Hyperactivity Disorder (ADHD), Dravet Syndrome), Prescription Mode (Prescription, OTC), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

EMEA Anorexiants Market Analysis and Size

According to the records of World Health Organization (WHO) report, around 650 million people and 41 million children under the age of 5 years were obese worldwide in 2017. Anorexiants are helping widely in this regard. The FDA has licensed several drugs for the treatment of obesity, the anorexiants market is expected to rise in the upcoming years. The increasing presence of major market players, a huge target population with disposable income in the EMEA is anticipated to surge the market growth during the forecast period 2023-2030.

Data Bridge Market Research analyses a growth rate in the EMEA anorexiants market in the forecast period 2023-2030. The expected CAGR of the EMEA anorexiants market tends to be around 3.2% in the mentioned forecast period. The market was valued at USD 124.7 million in 2022, and it would grow up to USD 160.4 million by 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

EMEA Anorexiants Market Scope and Segmentation

Market Definition

Anorexiants, often called appetite suppressants, are a kind of medication that is used to treat obesity. This medicine decreases food consumption by acting on the brain to hinder appetite. Anorexiants are CNS stimulants that helps to minimize appetite and are accessible as immediate and extended-release tablets. These prescription medications should be used in conjunction with a low-calorie diet and regular exercise.

EMEA Anorexiants Market Dynamics

Drivers

• Growing Occurrence of Obesity

The increasing incidence of obesity worldwide will boost the industry growth. Obesity is a  kind of condition in which the body fat levels have gathered to the point where they are causing health problems. When people intake more calories, this condition occurs. Obesity increases the risk of chronic diseases such as colon cancer, breast cancer, endometrial cancer, type 2 diabetes, cardiovascular disease, and musculoskeletal issues. According to the records of the World Health Organization, obesity affected around 650 million people and 340 million children and adolescents worldwide in 2016. Likewise, according to the Organization for Economic Co-operation and Development report in 2020, the EMEA is expected to spend the highest Health Expenditure on Obesity and Related Conditions worldwide during 2020-2050. This boosts the market growth.

• Rising Demand of Oral Supplements

Doctors widely prescribe oral anorexiants for the treatment of obesity. These drugs reduces hunger signals to the brain. Oral anorexiants are widely available in both prescription and over-the-counter (OTC) forms. There are several oral anorexiants that are manufactured by several market players such as diethylpropion, phendimetrazine, phentermine,  lorcaserin, bupropion/naltrexone, and topiramate/phentermine that helps in boosting the market growth.

Opportunities

• Rising Demand of Oral Route of Administration

Oral anorexiants dominated the market in past few years, and it is anticipated to do so during the forecast period. The increasing demand for these products can be because of the increased inclination of the patients due to their non-invasive treatment. Similarly, their easier administration without the need for trained healthcare professionals increased the adoption rate among the patients and physicians. Additionally, increasing availability of products in tablets and capsules, along with the increased awareness by major market players are anticipated to lead to the growth of the segment.

• Rise in Strategic Developments

Some of the major market players are employing numerous strategies such as increased investments in R&D and mergers and acquisitions. For instance, Currax Pharmaceuticals LLC, acquired Nalpropion Pharmaceuticals in September 2019 to focus on the treatment of weight loss. With the acquisition deal, Currax has owned the world-wide rights to Contrave, the number one prescription weight-loss brand medication in the EMEA and Europe.  This increases the market growth

Restraints/Challenges

• Lack of Skilled Professionals

Dearth of skilled healthcare professionals unaware of the appropriate use of anorexiants could reduce the growth of the EMEA anorexiants market during the forecast period 2023-2030. Otherwise use of these stimulants could affect the patient badly and lead to the hindrance of the market.

• Side Effects Associated with Anorexiants

There are various side effects that are linked with the anorexiants such as tachycardia, headache, diarrhea, myalgia, insomnia, vomiting, nausea and others will act as a limit and further hinder the growth rate of market

This EMEA anorexiants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the EMEA anorexiants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2020, VIVUS Inc. launched Qsymia in South Korea for weight loss management. This product launch aided the company in enlarging its foot print in emerging markets that helped it to overcome the losses arising from the established market.
• In 2019, Pfizer Inc. collaborated with Mylan N.V that primarily focused on manufacturing of large number of generic drugs which involves anorexiants drugs. This collaboration assisted the company in enhancing its market of generic anorexiants, which allowed it to earn more revenue growth.

EMEA Anorexiants Market Scope

The EMEA anorexiants market is segmented on the basis of drug class, drug type, applications, prescription mode, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Catecholamines Anorexiants
• Serotonin Anorexiants

Indication

• ADHD
• Dravet Syndrome
• Lennox-Gastaut Syndrome
• Obesity
• Weight Loss
• Others

Route of Administration

• Oral
• Subcutaneous
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Anorexiants Market Regional Analysis/Insights

The diabetic assays market is analyzed and market size insights and trends are provided by type, disease type, deployment, end-users and distribution channel as referenced above.

The major countries covered in the diabetic assays market report are Germany, France, U.K., Italy, Netherlands, Spain, Russia, Switzerland, Saudi Arabia, South Africa, Turkey, Austria, UAE, Israel, Norway, Hungary, Lithuania, Kuwait, Ireland, Egypt, Poland, Rest of Europe & Middle East and Africa.

Germany is dominating the market because of the availability of a wide variety of drugs, the increasing geriatric population, and the increasing demand for effective treatment. It is also because of wide presence of number of major market players dealing with the eating disorders and rising children and adult population.

France is the fastest-growing region because of the emerging economical condition and increasing investment of vendors to widely develop the drugs and also increasing prevalence of obesity and eating disorders.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and EMEA Anorexiants Market Share Analysis

The EMEA anorexiants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, EMEA presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to EMEA anorexiants market.

Key players operating in the EMEA anorexiants market include:

• VIVUS LLC (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Cipla Inc. (EMEA)
• Lannett (U.S.)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Novo Nordisk A/S (Denmark)
• Currax Pharmaceuticals LLC (U.S.)
• Eisai Co., Ltd. (Japan)
• Recordati Rare Diseases (Australia)
• Amphastar Pharmaceuticals, Inc (U.S.)